Mark R. Albertini

5.0k total citations
97 papers, 2.4k citations indexed

About

Mark R. Albertini is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Mark R. Albertini has authored 97 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 59 papers in Immunology and 24 papers in Molecular Biology. Recurrent topics in Mark R. Albertini's work include Immunotherapy and Immune Responses (44 papers), CAR-T cell therapy research (34 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Mark R. Albertini is often cited by papers focused on Immunotherapy and Immune Responses (44 papers), CAR-T cell therapy research (34 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Mark R. Albertini collaborates with scholars based in United States, Canada and Spain. Mark R. Albertini's co-authors include Paul M. Sondel, Jacquelyn A. Hank, Jacek Gan, Joan H. Schiller, Stephen D. Gillies, Jens C. Eickhoff, Heidi Schalch, Ralph A. Reisfeld, Cindy Zuleger and David M. Mahvi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Mark R. Albertini

90 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark R. Albertini United States 28 1.2k 1.1k 1.0k 334 332 97 2.4k
Gundram Jung Germany 31 1.4k 1.2× 1.7k 1.5× 871 0.9× 85 0.3× 729 2.2× 114 2.9k
Scott Ely United States 28 1.6k 1.3× 674 0.6× 1.3k 1.3× 127 0.4× 235 0.7× 89 3.4k
Alejandro Martı́n Spain 25 1.4k 1.1× 465 0.4× 845 0.8× 233 0.7× 183 0.6× 128 2.8k
Bernard Mariamé France 24 916 0.7× 782 0.7× 700 0.7× 196 0.6× 198 0.6× 46 2.3k
Christina Coughlin United States 21 839 0.7× 922 0.8× 682 0.7× 103 0.3× 86 0.3× 34 1.8k
TM Grogan United States 26 2.0k 1.6× 603 0.5× 1.0k 1.0× 315 0.9× 244 0.7× 58 3.6k
Mark Kirschbaum United States 25 2.1k 1.7× 1.7k 1.5× 1.9k 1.8× 258 0.8× 249 0.8× 66 6.2k
Nelly Robillard France 34 1.2k 1.0× 1.1k 0.9× 1.6k 1.5× 52 0.2× 363 1.1× 94 3.8k
Doriana Fruci Italy 31 1.3k 1.0× 1.8k 1.6× 1.3k 1.3× 445 1.3× 129 0.4× 82 3.3k
David R. Stover United States 23 1.1k 0.9× 401 0.4× 1.4k 1.4× 79 0.2× 360 1.1× 47 3.0k

Countries citing papers authored by Mark R. Albertini

Since Specialization
Citations

This map shows the geographic impact of Mark R. Albertini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Albertini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Albertini more than expected).

Fields of papers citing papers by Mark R. Albertini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Albertini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Albertini. The network helps show where Mark R. Albertini may publish in the future.

Co-authorship network of co-authors of Mark R. Albertini

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Albertini. A scholar is included among the top collaborators of Mark R. Albertini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Albertini. Mark R. Albertini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Albertini, Mark R., Cindy Zuleger, Erik A. Ranheim, et al.. (2024). Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma. Melanoma Research. 34(4). 307–318. 3 indexed citations
2.
Park, Yeonhee, Yusuf M. Mohamoud, Hamid Emamekhoo, et al.. (2023). Neutrophil‐to‐eosinophil ratio as a biomarker for clinical outcomes in advanced stage melanoma patients treated with anti‐PD‐1 therapy. Pigment Cell & Melanoma Research. 36(6). 501–511. 16 indexed citations
3.
Jin, Won Jong, Justin C. Jagodinsky, Paul A. Clark, et al.. (2023). NK cells propagate T cell immunity following in situ tumor vaccination. Cell Reports. 42(12). 113556–113556. 8 indexed citations
4.
Albertini, Mark R., et al.. (2021). Retrograde Balloon-Assisted Deep Enteroscopy in the Diagnosis of Metastatic Melanoma. SHILAP Revista de lepidopterología. 2021. 1–4. 1 indexed citations
5.
Scarpelli, M, et al.. (2021). Development and validation of a longitudinal soft-tissue metastatic lesion matching algorithm. Physics in Medicine and Biology. 66(15). 155017–155017. 9 indexed citations
6.
Yang, Richard K., Igor B. Kuznetsov, Erik A. Ranheim, et al.. (2020). Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2. Clinical Cancer Research. 26(13). 3296–3306. 17 indexed citations
7.
Tarhini, Ahmad A., Sandra J. Lee, Xiaoxue Li, et al.. (2018). E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. Clinical Cancer Research. 25(2). 524–532. 6 indexed citations
8.
Zuleger, Cindy, Erik A. Ranheim, Ilene D. Kurzman, et al.. (2017). Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanoma. Veterinary Medicine and Science. 3(3). 134–145. 10 indexed citations
9.
Albertini, Mark R., Erik A. Ranheim, Cindy Zuleger, et al.. (2016). Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma. Cancer Immunology Immunotherapy. 65(8). 897–907. 14 indexed citations
10.
Zuleger, Cindy, Michael D. Macklin, Bret L. Bostwick, et al.. (2010). In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells. Journal of Immunological Methods. 365(1-2). 76–86. 4 indexed citations
11.
Weber, Sharon M., et al.. (2006). Long-term Disease-free Survival After Adrenalectomy for Isolated Colorectal Metastases. Asian Journal of Surgery. 29(4). 291–293. 19 indexed citations
12.
Albertini, Mark R., Jacquelyn A. Hank, & Paul M. Sondel. (2005). Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma. PubMed. 22. 789–797. 8 indexed citations
13.
14.
Burlingham, William J., Satoshi Kusaka, Gholam‐Reza Hafez, et al.. (2001). Donor-derived small cell lung carcinoma in a kidney transplant recipient. Cancer. 92(9). 2429–2434. 17 indexed citations
15.
McCarthy, Donna O., et al.. (2000). Antigenicity of human melanoma cells transfected to express the B7-1 co-stimulatory molecule (CD80) varies with the level of B7-1 expression. Cancer Immunology Immunotherapy. 49(2). 85–93. 10 indexed citations
16.
Surfus, Jean E., Jacquelyn A. Hank, Egbert Oosterwijk, et al.. (1996). Anti-Renal-Cell Carcinoma Chimeric Antibody G250 Facilitates Antibody-Dependent Cellular Cytotoxicity with In Vitro and In Vivo Interleukin-2-Activated Effectors. Journal of Immunotherapy. 19(3). 184–191. 50 indexed citations
17.
Schiller, Joan H., Jacquelyn A. Hank, Barry E. Storer, et al.. (1993). A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.. PubMed. 53(6). 1286–92. 24 indexed citations
18.
Albertini, Mark R., et al.. (1993). Activation of Multiple Effector Mechanisms to Enhance Tumor lmmunotherapy. Journal of Immunotherapy. 14(4). 329–335. 12 indexed citations
19.
Albertini, Mark R., Steven Howard, Paul Fisch, et al.. (1993). Modulation of Target-Cell Culture Conditions Alters Susceptibility to Lymphocyte-Mediated Lysis. Journal of Immunotherapy. 13(4). 243–251. 1 indexed citations
20.
Sosman, Jeff, Kathleen Schell, Peter Köhler, et al.. (1991). Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom. Cancer Investigation. 9(1). 35–48. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gundram Jung Breakdown of academic impact, for papers by Scott Ely Breakdown of academic impact, for papers by Alejandro Martı́n Breakdown of academic impact, for papers by Bernard Mariamé Breakdown of academic impact, for papers by Christina Coughlin Breakdown of academic impact, for papers by TM Grogan Breakdown of academic impact, for papers by Mark Kirschbaum Breakdown of academic impact, for papers by Nelly Robillard Breakdown of academic impact, for papers by Doriana Fruci Breakdown of academic impact, for papers by David R. Stover
Rankless by CCL
2026